Search results for:

25 results

Discover our SPC booklet

Our Brussels IP/Life Sciences team has authored a booklet on the case-law of the Court of justice of the EU (CJEU) regarding supplementary protection certificates (SPCs).

Nynke Brouwer new senior associate at Stibbe

We are pleased to announce that Nynke Brouwer will be joining Stibbe’s Amsterdam office as senior associate. Her appointment as from 13 June 2022 will further strengthen our TMT/IP practice.

Podcast: Product counseling en intellectueel eigendom

In de nieuwe podcastaflevering van Stibbe Legal Insights spreken Femke van der Voort, gespecialiseerd in intellectueel eigendom, en Paul van der Hulst, mede-eigenaar en managing director van MoviĜo, over het beschermen van intellectuele eigendomsrechten.

Het federale regeerakkoord door een publiekrechtelijke bril

De nieuwe federale regering, die zichzelf een echte “hervormingsregering” noemt, heeft ambitieuze plannen voor het publiekrecht. In deze blogpost ontdek je enkele belangrijke hervormingen die de komende vijf jaar op de agenda staan.

Stibbe advises LDA Capital

Stibbe assisted LDA Capital, a US-based global investment group, with its capital commitment agreement with Mithra, a company dedicated to Women's Health.

Stibbe advises DW Healthcare Partners

Stibbe advised DW Healthcare Partners, a private equity investment firm, on the acquisition of CEFALY Technology, a company active in the healthcare sector.

Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe

Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe.

Stibbe advises pharmaceutical multinational

Stibbe assisted a pharmaceutical multinational in complex litigations.

Stibbe advises KBC Securities

Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels.

Stibbe advises worldwide seeds leader

Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors.

Product counseling en intellectueel eigendom

In deze podcastaflevering van Stibbe Legal Insights spreken Femke van der Voort, gespecialiseerd in intellectueel eigendom, en Paul van der Hulst, mede-eigenaar en managing director van MoviĜo, over het beschermen van intellectuele eigendomsrechten.

Stibbe advises leading pharmaceutical company

Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients.

Stibbe advises Mylan

Stibbe advises global pharmaceutical company Mylan on the merger control aspects of its USD 7.2 billion acquisition of Swedish drugmaker Meda.

Stibbe advises client in the pharmaceutical sector

Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.

Stibbe advises leading plasma protein biotherapeutics company

Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.

Stibbe advises biotech company

Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.

Stibbe advises major pharmaceutical company

Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.

Stibbe advises Cellerix

Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.

SearchSearch results for: “”